Friday Program

Education Session | Lunch Debates | EHA / ESH Joint Symposium | Meet-the-Expert | Opening Ceremony | Molecular Hematopoiesis Workshop | Poster Session I

EDUCATION SESSION
08:00 – 09:30 and 14:15 – 15:45, Hall A1

CHRONIC LYMPHOCYTIC LEUKEMIA
Chair: D Milligan (Birmingham Heartlands Hospital, Birmingham,
United Kingdom)

CLUES ON THE ORIGIN AND BEHAVIOUR OF CHRONIC
LYMPHOCYTIC LEUKEMIA CELLS
P Ghia (Università Vita-Salute San Raffaele, Milan, Italy)
PROGNOSTIC MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA
J Jurlander (Rigshospitalet, Copenhagen, Denmark)
CHRONIC LYMPHOCYTIC LEUKEMIA: THE ROLE OF STEM CELL
TRANSPLANTATION
P Dreger (Universitätsklinikum Heidelberg, Heidelberg, Germany)

EDUCATION SESSION
08:00 – 09:30 and 14:15 – 15:45, Hall A2

OTHER MONOCLONAL GAMMOPATHIES
Chair: H Ludwig (Wilhelminenspital, Vienna, Austria)

IMPACT OF SERUM FREE LIGHT CHAIN EVALUATION IN
MONOCLONAL GAMMOPATHY
A Dispenzieri (Mayo Clinic, Rochester, USA)
ADVANCES IN AL AMYLOIDOSIS
G Merlini (Biotechnology Research Laboratories, Pavia, Italy)
TREATMENT OF WALDENSTROEM MACROGLOBULINEMIA
E Kimby (Karolinska Institute, Stockholm, Sweden)

EDUCATION SESSION
08:00 – 09:30 and 14:15 – 15:45, Auditorium 1

ACUTE MYELOID LEUKEMIA
Chair: J Sierra (Hospital Santa Creu i Sant Pau, Barcelona, Spain)

GENE EXPRESSION PROFILING TO DISTINGUISH ACUTE MYELOID
LEUKEMIA SUBTYPES: DISCOVERY OF A NOVEL SUBTYPE WITH
UNIQUE MOLECULAR AND BIOLOGICAL FEATURES
R Delwel (Erasmus Medical Center, Rotterdam, The Netherlands)
GENETIC PROFILING AND ITS IMPACT ON TREATMENT OF
ACUTE MYELOID LEUKEMIA
H Döhner (University Hospital Ulm, Ulm, Germany)
NEW AGENTS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
S Amadori (Policlinico Tor Vergata, Rome, Italy)

EDUCATION SESSION
08:00 – 09:30 and 14:15 – 15:45, Hall A3

PEDIATRIC LEUKEMIA
Chair: A Biondi (University of Milano-Bicocca, Milan, Italy)

GENES AND PROTEINS MEDIATING DRUG RESISTANCE IN ACUTE
LYMPHOBLASTIC LEUKEMIA
R Pieters (Erasmus Medical Center, Rotterdam, The Netherlands)
CHARACTERISTICS AND MANAGEMENT OF PATIENTS WITH VERY
HIGH RISK CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
M Schrappe (University Medical Center, Kiel, Germany)
USING NOVEL TARGETED DRUG THERAPY FOR FRONT-LINE
MANAGEMENT OF PEDIATRIC ACUTE LEUKEMIA
G Reaman (The George Washington University School of Medicine
and Health Science, Bethesda, USA)

EDUCATION SESSION
08:00 – 09:30 and 14:15 – 15:45, Auditorium 2

CHRONIC MYELOID LEUKEMIA
Chair: F Guilhot (CHRU La Miletrie, Poitiers, France)

MOLECULAR MECHANISMS OF TRANSFORMATION AND
LEUKEMOGENESIS BY BCR-ABL
R van Etten (Tufts-New England Medical Center, Boston, USA)
IMATINIB RESISTANCE: THE ROLE OF BCR-ABL DEPENDENT AND
BCR-ABL INDEPENDENT MECHANISMS IN THE LOSS OF RESPONSE
TO TYROSINE KINASE INHIBITORS
G Martinelli (Institute of Hematology and Medical Oncology "Seràgnoli",
Bologna, Italy)
THE ROLE OF NEW AGENTS IN THE MANAGEMENT OF CHRONIC
MYELOID LEUKEMIA
M Deininger (Oregon Health & Science University, Portland, USA)

EDUCATION SESSION
08:00 – 09:30, Hall C1
14:15 – 15:45, Hall C5

CANCER AND THROMBOSIS
Chair: A Falanga (Ospedali Riuniti Bergamo, Bergamo, Italy)

HEMOSTASIS AND CANCER
F Rickles (The George Washington University, Washington, USA)
LOW MOLECULAR WEIGHT HEPARIN AND CANCER PROGRESSION
M Prins (Academic Hospital Maastricht, Maastricht, The Netherlands)
PROPHYLAXIS AND TREATMENT OF VENOUS THROMBOEMBOLISM
IN CANCER PATIENTS
G Agnelli (University of Perugia, Perugia, Italy)

EDUCATION SESSION
08:00 – 09:30 and 14:15 – 15:45, Hall C2

BLEEDING DISORDERS
Chair: F Peyvandi (University of Milan, Milan, Italy)

PAST AND PRESENT SCREENING ASSAYS TO EVALUATE HEMOSTASIS
W van Heerde (Radboud University Nijmegen Medical Center,
Nijmegen, The Netherlands)
EVALUATION OF THE SEVERITY OF BLEEDING DISORDERS
F Rodeghiero (San Bortolo Hospital, Vicenza, Italy)
TREATMENT OF BLEEDING DISORDERS WITH PRO-HEMOSTATIC DRUGS
J Ingerslev (Aarhus University Hospital Skejby, Aarhus, Denmark)

EDUCATION SESSION
08:00 – 09:30 and 16:00 – 17:30, Hall C3

NEUTROPHIL DISORDERS: A CLINICAL PERSPECTIVE
Chair: J Palmblad (Karolinska Institute, Stockholm, Sweden)

NEUTROPENIA: WHEN THE LACK OF NEUTROPHILS COUNTS
T Kuijpers (Academic Medical Center, Amsterdam, The Netherlands)
AUTOIMMUNE NEUTROPENIA
S Ehl (University Childrens Hospital Freiburg, Freiburg, Germany)
CHRONIC IDIOPATHIC NEUTROPENIA: CLINICAL AND
PATHOPHYSIOLOGIC ASPECTS
H Papadaki (University of Crete, Heraklion, Greece)

EDUCATION SESSION
08:00 – 09:30 and 14:15 – 15:45, Hall C4

TRANSFUSION
Chair: N Avent (University of the West of England, Bristol, United Kingdom)

MOLECULAR ORIGIN AND VARIABILITY OF THE RHESUS GENE
FAMILY: AN OVERVIEW OF EVOLUTION, GENETICS AND FUNCTION
C Huang (New York Blood Center, New York, USA)
BLOOD GROUP ANTIGENS STRUCTURE AND FUNCTION:
RECENT ADVANCES
J Cartron (INSERM, Paris, France)
CURRENT ASPECTS OF THE CLINICAL MANAGEMENT OF HEMOLYTIC
DISEASE OF THE NEWBORN AND FETUS
P Soothill (St. Michael's Hospital, North Somerset, United Kingdom)

EDUCATION SESSION
09:45 – 11:15 and 16:00 – 17:30, Hall A1

DIFFUSE LARGE B-CELL LYMPHOMA IN 2008
Chair: A López-Guillermo (University of Barcelona, Barcelona, Spain)

HOW TO TRANSLATE MOLECULAR PROGNOSTIC MARKERS
INTO CLINICAL PRACTICE?
H Stein (Charité - Universitätsmedizin Berlin, Berlin, Germany)
TREATING DIFFUSE LARGE B-CELL LYMPHOMA: OPTIMIZING
THE USE OF ANTI-CD20 ANTIBODIES
G Salles (Centre Hospitaire Lyon-Sud, Pierr-Benite, France)
TARGETED THERAPY OF DIFFUSE LARGE CELL LYMPHOMA
A Younes (M.D. Anderson Cancer Center, Houston, USA)

EDUCATION SESSION
09:45 – 11:15 and 16:00 – 17:30, Hall A2

MULTIPLE MYELOMA
Chair: J Cavenagh (St. Bartholomew's Hospital, London, United Kingdom)

CLINICAL IMPLICATIONS OF GENETIC ABNORMALITIES IN MYELOMA
J Drach (University of Vienna, Vienna, Austria)
FRONTLINE TREATMENT IN MULTIPLE MYELOMA PATIENTS INELIGIBLE
FOR STEM CELL TRANSPLANTATION
T Facon (Hôpital Claude Huriez, Lille, France)
TREATMENT OF RELAPSED MULTIPLE MYELOMA
J San Miguel (Hospital Universitario de Salamanca, Salamanca, Spain)

EDUCATION SESSION
09:45 – 11:15 and 16:00 – 17:30, Auditorium 1

MYELOPROLIFERATIVE DISORDERS
Chair: C Harrison (Guy's and St Thomas' NHS Foundation Trust,
London, United Kingdom)

STRATIFIED MANAGEMENT OF ESSENTIAL THROMBOCYTHEMIA
AND POLYCYTHEMIA VERA
A Vannucchi (University of Florence, Florence, Italy)
MANAGEMENT OF PRIMARY MYELOFIBROSIS
G Barosi (IRCCS Policlinico S Matteo Foundation, Pavia, Italy)
BLASTIC TRANSFORMATION IN MYELOPROLIFERATIVE DISORDERS:
SCIENCE AND THERAPY
R Mesa (Mayo Clinic, Rochester, USA)

EDUCATION SESSION
09:45 – 11:15 and 16:00 – 17:30, Hall A3

MYELODYSPLASTIC SYNDROMES
Chair: E Hellström-Lindberg (Karolinska Institute, Stockholm, Sweden)

PATHOGENESIS AND THERAPEUTIC TARGETS IN MYELODYSPLASTIC
SYNDROMES
S Boehrer (Institut gustave Roussy, Villejuif, France)
DEFINING THE ROLE OF EPIGENETIC THERAPY IN MYELODYSPLASTIC
SYNDROMES
S Gore (Johns Hopkins University, Baltimore, USA)
IMMUNOMODULATORY DRUGS (IMIDS) IN MYELODYSPLASTIC
SYNDROMES: LONG-TERM OUTCOME
A List (Moffitt Cancer Center, Tampa, USA)

EDUCATION SESSION
09:45 – 11:15 and 16:00 – 17:30, Auditorium 2

UPDATE IN HODGKIN’S LYMPHOMA
Chair: A Engert (University Hospital of Cologne, Cologne, Germany)

BIOLOGY OF HODGKIN LYMPHOMA
D Re (Centre Hospitalier Antibes, Antibes Cédex, France)
HODGKIN LYMPHOMA IN THE ELDERLY: CURRENT STATUS AND
FUTURE DIRECTIONS
S Proctor (University of Newcastle upon Tyne, Newcastle upon Tyne,
United Kingdom)
TREATMENT OPTIONS IN ADVANCED STAGE DISEASES
J Raemaekers (Radboud University Medical Center, Nijmegen,
The Netherlands)

EDUCATION SESSION
09:45 – 11:15, Hall C1
16:00 – 17:30, Hall C5

RED CELL DISORDERS
Chair: W van Solinge (University Medical Center Utrecht, Utrecht,
The Netherlands)

NEW INSIGHTS INTO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
L Luzzatto (Istituto Toscano Tumori and University of Firenze, Genova,
Italy)
MOLECULAR CONTROL OF HEMOGLOBIN F PRODUCTION AND
THE IMPLICATIONS FOR THERAPY
S Thein (King's College Hospital, London, United Kingdom)
NEW ADVANCES IN IRON CHELATION
R Galanello (Ospedale Microcitemico, Cagliari, Italy)

EDUCATION SESSION
09:45 – 11:15 and 16:00 – 17:30, Hall C2

PLATELET DISORDERS
Chair: B Godeau (CHU Henri Mondor, Creteil, France)

CONGENITAL PLATELET DISORDERS
M Cattaneo (Ospedale San Paolo - Università di Milano, Milan, Italy)
IMMUNOPATHOGENESIS, IMUNNOMODULATION AND MANAGEMENT
OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN
P Imbach (University Children's Hospital, Basel, Switzerland)
MANAGEMENT OF IMMUNE THROMBOCYTOPENIC PURPURA IN ADULTS
J Bussel (Weill-Cornell Medical College, New York, USA)

EDUCATION SESSION
09:45 – 11:15 and 14:15 – 15:45, Hall C3

STEM CELL TRANSPLANTATION
Chair: M Theobald (University Medical Center Utrecht, Utrecht,
The Netherlands)

CELLULAR THERAPY TO REBUILD IMMUNITY AFTER STEM CELL
TRANSPLANTATION
H Heslop (Baylor College of Medicine, Houston, USA)
IMMUNOLOGICAL AND CLINICAL ASPECTS OF DOUBLE CORD
BLOOD TRANSPLANTS
C Brunstein (University of Minnesota Medical School, Minneapolis, USA)
ALLOGENEIC TRANSPLANTS AND IMMUNE INTERVENTION IN
MULTIPLE MYELOMA
H Lokhorst (University Medical Center Utrecht, Utrecht,
The Netherlands)

EDUCATION SESSION
09:45 – 11:15 and 16:00 – 17:30, Hall C4

ACUTE LYMPHOBLASTIC LEUKEMIA
Chair: A Goldstone (University College Hospital, London, United Kingdom)

MOLECULAR PATHOGENESIS OF ACUTE LYMPHOBLASTIC LEUKEMIA:
AN IG/TCR-CENTRIC VIEW
E Macintyre (Hopital Necker/Enfants Malades, Paris, France)
RISK-ADAPTED THERAPY OF ACUTE LYMPHOBLASTIC LEUKEMIA
N Gökbuget (J.W. Goethe University Hospital, Frankfurt, Germany)
MANAGEMENT OF ADOLESCENTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA: IMPLICATIONS FOR ADULT THERAPY
D Webb (Great Ormaond Street Hospital, London, United Kingdom)